Skip to main content

Inbiomotion receives funding through the EU's Horizon 2020 programme

Images

Participants

Contact

Image
Press & Communications Section Head
Tel.+34 93 40 37255

In the final round of selection, the European Union's  Horizon 2020 programme has chosen two Catalan start-ups from the health sector: Inbiomotion and Peptomyc, which will receive €50,000 to fund their innovative projects and carry out feasibility studies on new ideas and products.

Inbiomotion, founded by Dr. Roger Gomis (ICREA research professor), is a spin-off of the IRB Barcelona and ICREA that was launched in late 2010 to develop biomarkers to predict bone metastasis in cancer patients from biopsies of primary tumors.

Read more here:
(English) http://www.biocat.cat/en/news/inbiomotion-and-peptomyc-receive-funding-through-european-horizon-2020-program

(Spanish) http://www.interempresas.net/Farmacia/Articulos/152129-Inbiomotion-y-Peptomyc-reciben-financiacion-del-programa-europeo-Horizon-2020.html

 

About IRB Barcelona

The Institute for Research in Biomedicine (IRB Barcelona) pursues a society free of disease. To this end, it conducts multidisciplinary research of excellence to cure cancer and other diseases linked to ageing. It establishes technology transfer agreements with the pharmaceutical industry and major hospitals to bring research results closer to society, and organises a range of science outreach activities to engage the public in an open dialogue. IRB Barcelona is an international centre that hosts 400 researchers and more than 30 nationalities. Recognised as a Severo Ochoa Centre of Excellence since 2011, IRB Barcelona is a CERCA centre and member of the Barcelona Institute of Science and Technology (BIST).